Key result
Statin use linked to ~70% lower odds of incident age-related maculopathy.
Case-Control (n=6,050)
No
Answers are grounded in this paper and cite their sources.
AIMS: To evaluate the association between age related maculopathy (ARM) and statin use. METHODS: A nested case-control study among patients at the Veterans Affairs Medical Center in Birmingham, Alabama, with newly diagnosed ARM (cases) between 1997 to 2001 were selected and age matched to non-ARM controls. RESULTS: 550 incident cases of ARM were identified and matched to 5500 controls. Overall, cases were 70% (OR 0.30, 95% CI 0.21 to 0.45) less likely to have received and filled a statin prescription relative to the controls. This association was present among both current and past (OR 0.34, 95% CI 0.21 to 0.53 and OR 0.26, 95% CI 0.14 to 0.47, respectively) statin users. When considering use of statin and/or non-statin lipid lowering medications, a significant risk reduction was observed for statin only users (OR 0.30, 95% CI 0.20 to 0.45) and combined statin and non-statin users (OR 0.20, 95% CI 0.06 to 0.64); there was no significant association for non-statin only users (OR 0.47, 95% CI 0.20 to 1.13). CONCLUSIONS: The results of this study suggest that subjects with ARM were significantly less likely to have filled a statin prescription. Future clinical research initiatives should include a clinical trial to provide direct evidence of the effectiveness of statins in lowering the incidence and progression of ARM.
No takes yet. Share an insight, caveat, or question.
Gerald McGwin (2003) conducted a case-control in Age-related maculopathy (ARM) (n=6,050). Statin use vs. No statin use (non-ARM controls) was evaluated on Incident age-related maculopathy (ARM) (OR 0.30, 95% CI 0.21-0.45). Statin use was associated with a 70% lower odds of incident age-related maculopathy compared with non-ARM controls (OR 0.30, 95% CI 0.21-0.45).
Synapse has enriched 10 related papers. Consider them for comparative context: